Fasenra vs Trelegy Ellipta
Side-by-side cost comparison based on Medicare Part D data
Fasenra
Benralizumab
Manufactured by AstraZeneca
Trelegy Ellipta
Fluticasone/Umeclidinium/Vilanterol
Manufactured by GlaxoSmithKline
Trelegy Ellipta costs 87% less per claim than Fasenra ($380.00 vs $2,836.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Fasenra | Trelegy Ellipta |
|---|---|---|
| Avg Cost Per Claim | $2,836.00 | $380.00 |
| Total Medicare Spending | $987.0M | $2.9B |
| Total Beneficiaries | 32,000 | 865,000 |
| Total Claims | 348,000 | 7,560,000 |
| Annual Cost/Patient | $30,844.00 | $3,325.00 |
| Year-over-Year Change | +18.6% | +19.8% |
| Generic Available | No | No |
| Patent Expiration | Nov 14, 2031 | Sep 26, 2030 |
| Manufacturer | AstraZeneca | GlaxoSmithKline |
| Condition | Asthma/COPD | Asthma/COPD |
| Generic Name | Benralizumab | Fluticasone/Umeclidinium/Vilanterol |
Fasenra vs Trelegy Ellipta: What the Data Shows
Fasenra (Benralizumab) and Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol) are both used to treat asthma/copd. Based on Medicare Part D data, Trelegy Ellipta costs $380.00 per claim, which is 87% less than Fasenra at $2,836.00 per claim.
Medicare spent $987.0M on Fasenra and $2.9B on Trelegy Ellipta. In terms of patient reach, Trelegy Ellipta serves more beneficiaries (865,000 vs 32,000).
Year-over-year spending changed +18.6% for Fasenra and +19.8% for Trelegy Ellipta. Fasenra saw significant spending growth, suggesting increased utilization or price increases. Trelegy Ellipta saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Fasenra patent expires Nov 14, 2031. Trelegy Ellipta patent expires Sep 26, 2030.
Frequently Asked Questions
Trelegy Ellipta is cheaper at $380.00 per claim, compared to $2,836.00 for Fasenra. That makes Trelegy Ellipta about 87% less expensive per claim based on Medicare Part D data.
Yes, both Fasenra and Trelegy Ellipta are used to treat asthma/copd. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Fasenra patent expires Nov 14, 2031. Trelegy Ellipta patent expires Sep 26, 2030.
Medicare Part D spent $987.0M on Fasenra covering 32,000 beneficiaries, and $2.9B on Trelegy Ellipta covering 865,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.